Found 6 clinical trials
-
Phase 2 trial
-
Accepting pediatric ages
-
Accepting adults
-
Currently Recruiting
Have been diagnosed with moderate to severe Ulcerative Colitis?
Have been diagnosed with moderate to severe Ulcerative Colitis?
- 72 views
- 08 Nov, 2020
- 1 location
-
Unknown Phase
-
Accepting pediatric ages
-
Accepting adults
-
Currently Recruiting
PSA-006
PSA-006
- 192 views
- 23 Nov, 2020
- 1 location
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Dermatology
-
Currently Recruiting
An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
This Phase 3 multicenter, randomized, placebo-controlled, double-blind study is designed to evaluate the efficacy and safety of apremilast in subjects with moderate to severe genital psoriasis (modified sPGA-G 3, moderate or severe). Approximately 332 subjects with moderate to severe genital psoriasis will be randomized 1:1 to receive either apremilast 30 …
- 210 views
- 23 Dec, 2020
- 120 locations
-
Multi-country trial
-
Phase 4 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Dermatology
-
Currently Recruiting
A Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Psoriatic Arthritis
This is a Phase 4, multicenter, single-arm, open-label study to evaluate the impact of apremilast, either in monotherapy or with stable Methotrexate (MTX), on Magnetic resonance imaging (MRI) outcomes in subjects with active PsA with up to 5 years of disease duration (since diagnosis).
- 190 views
- 12 Dec, 2020
- 99 locations
-
Multi-country trial
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Dermatology
-
Currently Recruiting
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque
- 98 views
- 16 Dec, 2020
- 192 locations
-
Multi-country trial
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Dermatology
-
Currently Recruiting
A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue to receive open-label apremilast therapy
- 0 views
- 23 Nov, 2020
- 6 locations